Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arvinas Inc (NQ: ARVN )

19.64 -0.15 (-0.76%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 471,929
Open 20.10
Bid (Size) 19.62 (21)
Ask (Size) 19.64 (6)
Prev. Close 19.79
Today's Range 19.14 - 20.15
52wk Range 19.14 - 57.96
Shares Outstanding 53,400,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Where Arvinas Stands With Analysts
Via Benzinga
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire

Performance

YTD
-41.13%
-41.13%
1 Month
-29.48%
-29.48%
3 Month
-22.00%
-22.00%
6 Month
-31.11%
-31.11%
1 Year
-54.11%
-54.11%

More News

Read More
7 Analysts Have This to Say About Arvinas
Via Benzinga
Barclays Maintains Overweight Rating for Arvinas: Here's What You Need To Know
Via Benzinga
Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
What 8 Analyst Ratings Have To Say About Arvinas
Via Benzinga
6 Analysts Have This to Say About Arvinas
Via Benzinga
Looking Into Arvinas's Return On Capital Employed
Via Benzinga
Where Arvinas Stands With Analysts
Via Benzinga
Arvinas and Pfizer Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant, an Investigational PROTAC® ER degrader being developed in ER+/HER2- Breast Cancer
From Arvinas Inc.
Via GlobeNewswire
Carrick Therapeutics Announces Clinical Trial Collaboration with Arvinas and Pfizer to Evaluate Samuraciclib and Vepdegestrant Combination
From CARRICK THERAPEUTICS LIMITED
Via GlobeNewswire
Arvinas Announces Changes to its Board of Directors
From Arvinas Inc.
Via GlobeNewswire
Arvinas: Q1 Earnings Insights
Via Benzinga
Arvinas Earnings Perspective: Return On Capital Employed
Via Benzinga
Arvinas Releases Early Cut Data Showing Encouraging Efficacy In Prostate Cancer With Certain Mutations
Via Benzinga
Arvinas Announces Interim Data from the ARV-766 Phase 1/2 Dose Escalation and Expansion Trial Showing Promising Signals of Efficacy in Late-line mCRPC, Including in Patients with AR L702H Mutations
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Via Investor's Business Daily
Warner Bros. Discovery To Rally Around 62%? Here Are 10 Other Analyst Forecasts For Monday
Via Benzinga
Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentations at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
From Arvinas Inc.
Via GlobeNewswire
Arvinas Reports First Quarter 2023 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Present at the Bank of America Securities 2023 Healthcare Conference
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Present at Stifel Targeted Oncology Day
From Arvinas Inc.
Via GlobeNewswire
Arvinas Appoints Kelly Page as Senior Vice President, Global Head of Oncology Strategy and Program Leadership
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.